Core Viewpoint - The last six months have been more challenging for Merit Medical than expected, with tariffs acting as a volatile but net-negative earnings driver [1] Group 1 - Merit Medical has faced unexpected challenges in the past six months [1] - Tariffs have contributed to earnings volatility, negatively impacting the company's financial performance [1]

Core Insights - The Cooper Companies (COO) is currently more attractive to value investors compared to Merit Medical (MMSI) based on various financial metrics and rankings [1][3][7] Valuation Metrics - COO has a forward P/E ratio of 18.10, while MMSI has a forward P/E of 24.27, indicating that COO is potentially undervalued [5] - The PEG ratio for COO is 1.79, compared to MMSI's PEG ratio of 2.39, suggesting that COO has a better balance between price and expected earnings growth [5] - COO's P/B ratio is 1.77, significantly lower than MMSI's P/B of 3.51, further supporting the argument that COO is more attractively valued [6] Rankings and Grades - COO holds a Zacks Rank of 2 (Buy), while MMSI has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for COO [3] - The Value grade for COO is B, whereas MMSI has a Value grade of C, reflecting the superior valuation metrics of COO [6]

Core Insights - Merit Medical Systems, Inc. has successfully enrolled the first patient in the WRAP North America registry, aimed at evaluating the WRAPSODY Cell-Impermeable Endoprosthesis (CIE) for patients on hemodialysis experiencing vascular access obstructions [1][2][5] Group 1: WRAP North America Registry - The WRAP North America registry is designed to enroll up to 250 patients in the US and Canada who are on hemodialysis and face obstructions in their vascular access [2][4] - The study will evaluate clinical outcomes over a three-year period for patients treated with the WRAPSODY CIE [2][4] - The first patient was enrolled by Dr. Omar Davis, highlighting the importance of this registry in assessing the device's effectiveness [2][3] Group 2: WRAPSODY CIE Device - The WRAPSODY CIE has shown superior performance in previous clinical trials, specifically the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial [3][4] - The WAVE trial compared outcomes of patients treated with WRAPSODY CIE versus those treated with percutaneous transluminal angioplasty (PTA) [3] - The WRAPSODY CIE received premarket approval from the FDA on December 19, 2024, and was subsequently approved by Health Canada on April 30, 2025 [7] Group 3: Future Prospects - The WRAP North America registry aims to contribute to a growing portfolio of clinical evidence supporting the WRAPSODY CIE, potentially representing the largest cohort of patients treated with an implantable device for vascular access restoration [4][5] - A parallel WRAP Global registry is also being conducted to evaluate real-world outcomes, with an expected final enrollment of up to 500 patients outside North America by the end of 2025 [5][6]

Core Insights - Merit Medical Systems, Inc. has successfully enrolled the first patient in the WRAP North America registry, aimed at evaluating the WRAPSODY Cell-Impermeable Endoprosthesis (CIE) for patients on hemodialysis [1][5][8] Group 1: WRAP North America Registry - The WRAP North America registry is designed to enroll up to 250 patients in the US and Canada who are on hemodialysis and experience vascular access obstructions [2][4] - The registry will evaluate clinical outcomes over three years for patients treated with the WRAPSODY CIE [2][4] - The first patient was enrolled by Dr. Omar Davis at Bluff City Vascular, marking a significant milestone for the company [2][5] Group 2: WRAPSODY CIE Device - The WRAPSODY CIE aims to restore vascular access for hemodialysis patients facing obstructions, with promising results demonstrated in the previous WAVE pivotal trial [3][4] - The WAVE trial compared the WRAPSODY CIE with percutaneous transluminal angioplasty (PTA) and historical outcomes of patients treated with previous-generation covered stents [3] - The device received premarket approval from the FDA on December 19, 2024, and was approved by Health Canada on April 30, 2025 [7] Group 3: Clinical Evidence and Future Prospects - The WRAP North America registry is expected to contribute to a growing portfolio of clinical evidence supporting the WRAPSODY CIE [4] - A parallel WRAP Global registry is also being conducted to enroll up to 500 patients outside North America, with final enrollment expected by the end of 2025 [5] - The company emphasizes the importance of real-world effectiveness data to address critical questions regarding the device's broader impact in clinical practice [4][5]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

Core Insights - Merit Medical Systems, Inc. has launched the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology, aimed at enhancing radial access procedures and potentially reducing arterial spasm and occlusion [1][2] Product Features - The Prelude Wave is part of Merit's Access portfolio, featuring a low-profile, hydrophilic design that offers best-in-class insertion and sheath retention [2] - The sheath is designed to reduce risks associated with radial artery spasm, which occurs in up to 20% of patients, and occlusion, which affects approximately 4.6% of patients [3][4] - The Prelude Wave provides twice the lubricity, resistance to buckling and kinking, and requires 40% less insertion force compared to leading competitors [6] Clinical Impact - The introduction of SnapFix technology offers twice the adhesive strength, enhancing the performance and ease of use for physicians [6] - The securement devices used for stabilizing hydrophilic sheaths have been linked to procedural inefficiencies in 30% of cases, indicating a significant need for improved solutions [5] Strategic Positioning - Merit Medical aims to support a radial-first approach by complementing existing products and addressing clinical challenges, as demonstrated by its acquisition of StatSeal®, a hemostatic sealant for radial procedures [8] - The company emphasizes its commitment to innovation in its Access portfolio, providing healthcare partners with data-driven treatment solutions [9]

Merit Medical Systems (MMSI 2.29%), a medical device developer serving cardiovascular and endoscopy markets, reported results for its second quarter ended June 30, 2025, on July 30, 2025. The company posted GAAP revenue of $382.5 million, up 13.2% from the prior year and above the analyst consensus of $374.2 million (GAAP). Non-GAAP earnings per share (EPS) reached $1.01, beating the $0.85 estimate. Reported GAAP EPS, however, declined 11.6% to $0.54. The quarter showed solid broad-based growth, especially ...

Core Insights - Merit Medical Systems, Inc. (MMSI) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.01, reflecting a 9.8% increase year over year and surpassing the Zacks Consensus Estimate by 17.4% [1][9] - The company's total revenues reached $382.5 million, marking a 13.2% year-over-year increase [2][9] Revenue Details - Revenues increased by 12.5% year over year at constant exchange rates (CER), with organic revenues rising 6.7% [2] - U.S. sales were $227.1 million, up 16.7% year over year, while international sales reached $155.4 million, up 8.4% [3][4] Geographic Results - Asia-Pacific (APAC) revenues were $66.6 million, down 0.4% year over year, while revenues from Europe, the Middle East, and Africa were $72.6 million, up 16.5% [4] - Revenues from the Rest of World region were $16.2 million, up 13.9% year over year [5] Segmental Details - The Cardiovascular segment reported revenues of $364 million, up 11% year over year [6] - Within the Cardiovascular unit, Cardiac Intervention (CI) revenues rose 23.5% to $115.3 million, while Peripheral Intervention (PI) revenues increased 6.3% to $142.8 million [7][8] Margin Analysis - Gross profit increased 14.5% year over year to $184.5 million, with a gross margin of 48.2% [11] - Adjusted operating profit totaled $47 million, reflecting a 1.7% increase from the prior year, although the adjusted operating margin contracted to 12.3% [12] Financial Position - At the end of the second quarter, cash and cash equivalents were $341.8 million, down from $395.5 million at the end of the first quarter [13] - Total long-term debt was $731.8 million, slightly up from $730.7 million in the previous quarter [13] Guidance - The company revised its 2025 revenue outlook to between $1.495 billion and $1.507 billion, reflecting a year-over-year increase of 10.2-11.1% [14] - Adjusted EPS for 2025 is now projected to be in the range of $3.52-$3.72, an increase from the previous outlook [17] Strategic Developments - In May, the company acquired Biolife Delaware, L.L.C., enhancing its portfolio [20] - The approval of the Wrapsody Cell-Impermeable Endoprosthesis by Health Canada is expected to positively impact the company [20]

Core Insights - Merit Medical reported revenue of $382.46 million for the quarter ended June 2025, reflecting a 13.2% increase year-over-year, with EPS at $1.01 compared to $0.92 in the previous year [1] - The reported revenue met the Zacks Consensus Estimate, while the EPS exceeded the consensus estimate by 17.44% [1] Financial Performance Metrics - U.S. sales reached $227.08 million, surpassing the estimated $220.3 million, marking a 16.7% increase from the same quarter last year [4] - International sales amounted to $155.38 million, exceeding the estimated $151.04 million, representing an 8.4% year-over-year growth [4] - Revenue from Cardiovascular-Peripheral Intervention was $142.85 million, slightly below the estimated $144.62 million, with a year-over-year increase of 2.6% [4] - Cardiovascular-Cardiac Intervention revenue was $115.25 million, exceeding the estimated $104.93 million, showing a significant 22.8% increase year-over-year [4] - Endoscopy revenue reached $18.44 million, slightly below the estimated $18.66 million, but reflecting an impressive 81% increase from the previous year [4] - Cardiovascular-OEM revenue was $52.29 million, close to the estimated $52.65 million, with an 18.1% year-over-year increase [4] - Total Cardiovascular revenue was $364.03 million, surpassing the estimated $353.56 million, indicating an 11.1% increase year-over-year [4] - Revenue from Cardiovascular-Custom Procedural Solutions was $53.63 million, exceeding the estimated $51.05 million, with a year-over-year growth of 6.4% [4] Stock Performance - Merit Medical's shares have declined by 11.8% over the past month, contrasting with a 3.4% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported total revenue of $382.5 million, up 13% year over year on a GAAP basis and up 12.5% year over year on a constant currency basis, exceeding growth expectations [8][9] - Non-GAAP operating margin increased nearly 109 basis points year over year to 21.2%, representing the highest performance in the company's history as a public company [9] - Non-GAAP EPS grew by 10%, exceeding expectations, and free cash flow increased by 20% year over year to $70 million [9][32] Business Line Data and Key Metrics Changes - Cardiovascular segment sales grew by 10% and endoscopy segment sales increased by 81% [24] - Cardiac intervention product sales rose by 23%, with organic growth of approximately 10% [25] - Peripheral intervention products and custom procedure solutions saw sales increases of 6% and above expectations, respectively [25] Market Data and Key Metrics Changes - U.S. sales increased by 17% on a constant currency basis and 10% on an organic constant currency basis [28] - International sales grew by 7% year over year, with a 2% increase on an organic constant currency basis [28] - Sales in China decreased by 6%, attributed to the broader macro environment [29][80] Company Strategy and Development Direction - The company announced the acquisition of BioLife Delaware LLC for $120 million, aimed at enhancing its product offerings in hemostatic solutions [10][11] - A comprehensive marketing plan for the Rhapsody CIE was launched, focusing on expanding physician relationships and securing reimbursement coverage [15][16] - The company is targeting a premium pricing strategy for the Rhapsody CIE, emphasizing its unique treatment options and clinical benefits [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong execution and revenue growth despite a challenging global macro environment [10] - The company acknowledged a two-quarter delay in securing add-on reimbursement for the Rhapsody CIE in the outpatient setting but maintained long-term growth expectations [22][37] - Management emphasized the importance of their reimbursement strategy and ongoing engagement with CMS to secure necessary approvals [21][56] Other Important Information - The company updated its 2025 financial guidance, expecting GAAP net revenue growth of 10% to 11% and non-GAAP diluted EPS in the range of $3.52 to $3.72 [34][39] - The anticipated impact of tariffs on cost of goods was revised down to approximately $7 million, reflecting better-than-expected performance [38] Q&A Session Summary Question: Clarification on Rhapsody reimbursement process - Management clarified that they applied for a new technology APC assignment but did not receive it, and they plan to submit for TPT by September 1 [46][48] Question: Confidence in securing TPT - Management expressed high confidence in meeting TPT guidelines and emphasized the strength of their product data [55][60] Question: Sales performance in cardiac intervention - Management attributed the sales uplift to internal product development and the strategic acquisition of Cook Medical [100][106]